PLA2G2E: A Drug Target / Disease Biomarker (G30814)

Target Name: PLA2G2E

NCBI ID: G30814

PLA2G2E

PLA2G2E: A Drug Target / Disease Biomarker

PLA2G2E, also known as CD28, is a protein that is expressed in many different tissues throughout the body. It is a member of the CD28 superfamily, which includes proteins that are involved in cell-cell adhesion, migration, and signaling. One of the things that makes PLA2G2E unique is its ability to interact with the protein PD-L1, which is a negative regulator of T cell immunity. This interaction between PLA2G2E and PD-L1 has important implications for the development and treatment of autoimmune diseases.

PLA2G2E is a 28-kDa protein that is expressed in many different tissues, including the brain, heart, kidneys, and liver. It is characterized by a string of 28 amino acid residues that are involved in its structure and function. PLA2G2E is involved in several different cellular processes, including cell adhesion, migration, and signaling.

One of the most interesting things about PLA2G2E is its ability to interact with the protein PD-L1. PD-L1 is a negative regulator of T cell immunity, and it is involved in preventing the activation and proliferation of T cells. In diseases such as cancer, T cells can become overactive and contribute to the development and progression of the disease. By interacting with PD-L1, PLA2G2E may be able to promote the activation and proliferation of T cells, which could be a potential therapeutic approach for treating these diseases.

PLA2G2E has also been shown to play a role in cell migration. During the development and progression of cancer, cells can migrate away from their original tumors and establish new colonies. By interacting with PD-L1, PLA2G2E may be able to regulate the migration of cancer cells, which could be a potential therapeutic approach for treating cancer.

In addition to its role in cell adhesion, migration, and signaling, PLA2G2E is also involved in the regulation of inflammation. Chronic inflammation can contribute to the development and progression of many different diseases, including autoimmune diseases. By interacting with PD-L1, PLA2G2E may be able to regulate the inflammation that contributes to the development and progression of these diseases.

PLA2G2E is also involved in the regulation of cell survival. Chronic inflammation can cause damage to tissues and lead to the death of cells. By interacting with PD-L1, PLA2G2E may be able to protect cells from the effects of chronic inflammation, which could be a potential therapeutic approach for treating many different diseases.

In conclusion, PLA2G2E is a protein that is involved in a wide range of cellular processes that are important for the development and progression of many different diseases. Its ability to interact with the protein PD-L1 makes it a potential drug target and a promising biomarker for the treatment of autoimmune diseases. Further research is needed to fully understand the role of PLA2G2E in these diseases and to develop effective treatments.

Protein Name: Phospholipase A2 Group IIE

Functions: Secretory calcium-dependent phospholipase A2 that primarily targets extracellular phospholipids (PubMed:10681567, PubMed:11922621, PubMed:28883454). Hydrolyzes the ester bond of the fatty acyl group attached at sn-2 position of phospholipids (phospholipase A2 activity), releasing various unsaturated fatty acids including oleoate, linoleoate, arachidonate, docosahexaenoate and lysophosphatidylethanolamines in preference to lysophosphatidylcholines (PubMed:10681567, PubMed:28883454). In response to high-fat diet, hydrolyzes minor lipoprotein phospholipids including phosphatidylserines, phosphatidylinositols and phosphatidylglycerols, altering lipoprotein composition and fat storage in adipose tissue and liver (By similarity). May act in an autocrine and paracrine manner (PubMed:11922621). Contributes to lipid remodeling of cellular membranes and generation of lipid mediators involved in pathogen clearance. Cleaves sn-2 fatty acyl chains of phosphatidylglycerols and phosphatidylethanolamines, which are major components of membrane phospholipids in bacteria (PubMed:11922621). Acts as a hair follicle phospholipase A2. Selectively releases lysophosphatidylethanolamines (LPE) and various unsaturated fatty acids in skin to regulate hair follicle homeostasis (By similarity). May regulate the inflammatory response by releasing arachidonate, a precursor of prostaglandins and leukotrienes (PubMed:11922621). Upon allergen exposure, may participate in allergic inflammatory response by enhancing leukotriene C4 synthesis and degranulation in mast cells (By similarity)

The "PLA2G2E Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PLA2G2E comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets